NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
NLX-112 is a potent and selective 5-HT1A agonist that has successfully completed a Phase 2A clinical trial for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease (PD) patients. Here, we investigated the neuroprotective activity of NLX-112 in a mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD. Four groups of male mice received subcutaneous administrations of either saline (1 mL/kg) daily for 15 days, MPTP (21.4 mg/kg for 5 days, preceded and followed by 5 days of saline, NLX-112 (1 mg/kg/day for 15 days), or combined MPTP + NLX-112. Two weeks following the cessation of treatments, mice treated with NLX-112 alone or NLX-112/MPTP showed increased locomotor activity and reduced anxiety-like behavior (as assessed by a 40% reduction of thigmotaxis) in an open-field test, consistent with sustained effects of 5-HT1A receptor activation. MPTP-treated mice showed a 40% reduction of dopaminergic (i.e., tyrosine hydroxylase immunoreactive; TH-ir) neurons in the substantia nigra compacta (SNc) and a 55% reduction of nerve terminals in the striatum. NLX-112 treatment completely prevented TH-ir neuron loss and reduced MPTP-induced dopamine nerve terminal loss to 30%. MPTP also markedly increased the levels of GFAP-ir astrocytes and Iba1-ir microglia in the SN, as well as coexpression of glial-derived neurotrophic factor (GDNF) in the GFAP-ir astrocytes in both the SNc and the striatum. NLX-112 markedly reversed this MPTP-induced microglial overactivation in the SNc, and upregulated GFAP/GDNF colocalization in both the striatum and the SNc. Overall, the present study demonstrates a robust neuroprotective effect of NLX-112 in a mouse model of PD by preventing microgliosis, upregulating GDNF, and favoring sustained pro-locomotor activity.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.